Mereo Debt to Equity

MREO
 Stock
  

USD 0.75  0.03  3.85%   

Mereo Biopharma Group fundamentals help investors to digest information that contributes to Mereo Biopharma's financial success or failures. It also enables traders to predict the movement of Mereo Stock. The fundamental analysis module provides a way to measure Mereo Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mereo Biopharma stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Mereo Debt to Equity Analysis

Mereo Biopharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
D/E 
 = 
Total Debt 
Total Equity 
More About Debt to Equity | All Equity Analysis

Current Mereo Biopharma Debt to Equity

    
  0.19 %  
Most of Mereo Biopharma's fundamental indicators, such as Debt to Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mereo Biopharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Compare to competition

According to the company disclosure, Mereo Biopharma Group has a Debt to Equity of 0.19%. This is 99.65% lower than that of the Healthcare sector and 99.02% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 99.61% higher than that of the company.

Mereo Debt to Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mereo Biopharma's direct or indirect competition against its Debt to Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mereo Biopharma could also be used in its relative valuation, which is a method of valuing Mereo Biopharma by comparing valuation metrics of similar companies.
Mereo Biopharma is currently under evaluation in debt to equity category among related companies.

Mereo Fundamentals

About Mereo Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mereo Biopharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo Biopharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mereo Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Mereo Biopharma Piotroski F Score and Mereo Biopharma Altman Z Score analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
95.9 M
Return On Assets
(0.21) 
Return On Equity
(0.25) 
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.